108 results
Page 3 of 6
8-K
EX-99.1
9a27ir35auk bdw
3 Nov 21
Karyopharm Reports Strong Third Quarter 2021 Financial Results and Provides Business
7:10am
8-K
EX-99.1
d8o 0p5691md1hp
5 Aug 21
Karyopharm Reports Business Highlights and Second Quarter 2021 Financial Results
7:11am
8-K
EX-99.1
2ar e3g786f15s0b
3 May 21
Karyopharm Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress
7:20am
8-K
EX-99.1
p5gf4vdlgz y2voo
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
2wfzbjz9
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
c8gwzki
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.1
kxqshwa3tepdy5n
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.2
q7jbe vrf11ishf
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
vfwei a0g
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
tfyx oln1
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
EX-99.1
tkaemknp
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
8-K
EX-1.1
fec dp2srz
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm